Immuno-Oncology | Specialty

Krista Rubin on Managing Ipilimumab-related Dermatitis

May 6th 2012

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

May 4th 2012

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Sartor on Combining Radium-223 and Provenge

April 25th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Gomella Suggests Provenge Benefit Understated

April 20th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

Revised View Enhances Provenge OS Data

April 19th 2012

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Gomella on the Cost of the Immunotherapy Sipuleucel-T

March 1st 2012

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Alter Discusses the Provenge Treatment Process

November 17th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Alter Discusses the Immunotherapy Provenge

November 11th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Dr. Hoos Discusses the Next Steps for Ipilimumab

August 9th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab

August 3rd 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Dr. Hoos on the Ipilimumab Plus Dacarbazine Trial

July 29th 2011

Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Aiming for Immunity: New Therapies in Sights

July 14th 2011

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Schuchter on Managing Ipilimumab's Side Effects

July 13th 2011

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy